SecBot SecBot
SECBOTREPLAY Home › Report › TBPH

TBPH · Theravance Biopharma's Phase 3 CYPRESS study for ampreloxetine failed…

Theravance Biopharma, Inc. · 8-K filed Mar 3, 2026 at 08:35 ET

At the news

BEARISHIMPACT 8/10

8-K filed Mar 3, 2026 at 08:35 ET

Theravance Biopharma's Phase 3 CYPRESS study for ampreloxetine failed to meet its primary endpoint, prompting the company to wind down the program. In response, the company is restructuring, cutting costs by ~60% ($70M), reducing its workforce by ~50%, and accelerating a strategic review that could include a sale. Despite the setback, the company maintains a strong cash position (~$400M expected) and a profitable commercial product, YUPELRI.

  • Phase 3 CYPRESS study for ampreloxetine failed to meet primary endpoint (OHSA Composite Score).
  • Company is winding down the ampreloxetine program and its entire R&D function.
  • Organizational restructuring will reduce operating expenses by ~60% (~$70 million) and impact ~50% of the workforce.
  • Strategic Review Committee is accelerating its review of alternatives to maximize shareholder value, including a potential sale of the company.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access